首页 > 市场调查报告书 > 製药

生物製剂

市场调查报告书

商品编码

1406662

重组蛋白市场 - 2018-2028 年全球产业规模、份额、趋势、机会与预测，按产品、按应用、地区、竞争细分

Recombinant Protein Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product, By Application, By Region, By Competition

出版日期: 2023年11月07日 | 出版商:

TechSci Research | 英文 175 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2022 年全球重组蛋白市场价值为 21.9 亿美元，预计在预测期内将强劲增长，到 2028 年CAGR为7.34%。重组蛋白是使用重组DNA (rDNA) 技术合成的，该技术涉及将至少两种DNA 序列在自然界中通常不会同时出现。然后仔细检查这些 rDNA 文库和所得蛋白质作为疾病途径抑制剂、替代疗法或其他抗疾病药物的潜在用途。

重组蛋白的生产从基因水平开始，其中所需蛋白的编码序列被分离并克隆到表达质粒载体中。儘管大多数治疗性重组蛋白源自人类基因，但它们在酵母、细菌或培养的动物细胞等微生物中表现。近年来，有效的瞬时转染方案得到了发展，HEK293 衍生的细胞系经常用于蛋白质的瞬时生产。哺乳动物细胞目前是生产重组治疗性蛋白质的优选宿主，因为它们能够产生与人类中发现的高品质蛋白质相同的蛋白质。此外，许多经批准的重组治疗蛋白都是在大肠桿菌中产生的，因为它生长迅速、遗传学特征良好且产量高。

主要市场驱动因素

市场概况
预测期	2024-2028
2022 年市场规模	21.9亿美元
2028 年市场规模	33.7亿美元
2023-2028 年CAGR	7.34%
成长最快的细分市场	荷尔蒙
最大的市场	北美洲

生物製药进展

市场规模及预测
- 按价值
市占率及预测
- 副产品（荷尔蒙、生长因子、抗体、酵素、其他）
- 按应用（研究应用、治疗用途、生技产业）
- 按地区（北美、欧洲、亚太地区、南美、中东和非洲）
- 按公司划分 (2022)
市场地图
- 按产品分类
- 按应用
- 按地区

第 6 章：北美重组蛋白市场展望

市场规模及预测
- 按价值
市占率及预测
- 副产品（荷尔蒙、生长因子、抗体、酵素、其他）
- 按应用（研究应用、治疗用途、生技产业）
- 按国家/地区
北美：国家分析
- 美国
- 加拿大
- 墨西哥

第 7 章：欧洲重组蛋白市场展望

市场规模及预测
- 按价值
市占率及预测
- 副产品（荷尔蒙、生长因子、抗体、酵素、其他）
- 按应用（研究应用、治疗用途、生技产业）
- 按国家/地区
欧洲：国家分析
- 法国
- 德国
- 英国
- 义大利
- 西班牙

第 8 章：亚太地区重组蛋白市场展望

市场规模及预测
- 按价值
市占率及预测
- 副产品（荷尔蒙、生长因子、抗体、酵素、其他）
- 按应用（研究应用、治疗用途、生技产业）
- 按国家/地区
亚太地区：国家分析
- 中国
- 印度
- 日本
- 韩国
- 澳洲

第 9 章：南美洲重组蛋白市场展望

市场规模及预测
- 按价值
市占率及预测
- 副产品（荷尔蒙、生长因子、抗体、酵素、其他）
- 按应用（研究应用、治疗用途、生技产业）
- 按国家/地区
南美洲：国家分析
- 巴西
- 阿根廷
- 哥伦比亚

第 10 章：中东和非洲重组蛋白市场展望

市场规模及预测
- 按价值
市占率及预测
- 副产品（荷尔蒙、生长因子、抗体、酵素、其他）
- 按应用（研究应用、治疗用途、生技产业）
- 按国家/地区
MEA：国家分析
- 南非重组蛋白
- 沙乌地阿拉伯重组蛋白
- 阿联酋重组蛋白

第 11 章：市场动态

司机
挑战

第 12 章：市场趋势与发展

近期发展
併购
产品发布

第 13 章：全球重组蛋白市场：SWOT 分析

第 14 章：波特的五力分析

产业竞争
新进入者的潜力
供应商的力量
客户的力量
替代产品的威胁

第15章：竞争格局

艾伯维公司
- Business Overview
- Product Offerings
- Recent Developments
- Financials (As Reported)
- Key Personnel
- SWOT Analysis
安进公司
Bio-Rad 实验室公司
礼来公司
默克公司
诺和诺德公司
赛诺菲公司
赛默飞世尔科技公司
诺华公司
葛兰素史克公司
诺瓦瓦克斯公司
辉瑞公司

第 16 章：策略建议

简介目录

Product Code: 19875

Global Recombinant Protein Market has valued at USD 2.19 Billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 7.34% through 2028. Recombinant proteins are synthesized using recombinant DNA (rDNA) technology, which involves combining at least two DNA sequences not typically found together in nature. These rDNA libraries and the resultant proteins are then scrutinized for their potential use as disease pathway inhibitors, replacement therapies, or other anti-disease agents.

The production of recombinant proteins initiates at the genetic level, where the coding sequence of the desired protein is separated and cloned into an expression plasmid vector. Although most therapeutic recombinant proteins are derived from human genes, they are expressed in microorganisms such as yeast, bacteria, or animal cells in culture. Recent years have seen the development of effective transient transfection protocols, and HEK293-derived cell lines are frequently used for the transient production of proteins. Mammalian cells are presently the preferred host for producing recombinant therapeutic proteins due to their ability to produce high-quality proteins like to those found in humans. Additionally, many approved recombinant therapeutic proteins are produced in E.coli because of its rapid growth, well-characterized genetics, and high-yield production.

Key Market Drivers

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 2.19 Billion
Market Size 2028	USD 3.37 Billion
CAGR 2023-2028	7.34%
Fastest Growing Segment	Hormone
Largest Market	North America

Biopharmaceutical Advancements

Biopharmaceutical advancements are poised to catalyze substantial growth in the global recombinant protein market. The convergence of cutting-edge biotechnologies, such as CRISPR-Cas9 gene editing and advanced cell culture techniques, is enabling the development of novel and highly efficient methods for producing recombinant proteins. This enhanced production capability translates into a more robust and diversified pipeline of therapeutic proteins, meeting the escalating demand for innovative biopharmaceuticals.

Moreover, advancements in protein engineering are facilitating the creation of bioengineered proteins with improved therapeutic properties, enhancing their efficacy and safety profiles. The relentless pursuit of precision medicine and personalized therapies is also driving the demand for recombinant proteins tailored to specific patient populations. This customization, enabled by biopharmaceutical breakthroughs, not only enhances therapeutic outcomes but also opens new avenues for market expansion. As biopharmaceutical companies continue to invest in research and development, leveraging state-of-the-art technologies, the global recombinant protein market is poised for sustained growth. The interplay of innovation, scalability, and a responsive regulatory environment positions this market at the forefront of the biopharmaceutical industry's evolution, offering lucrative opportunities for stakeholders across the value chain.

Technological Advancements in Protein Expression Systems

Technological advancements in protein expression systems are pivotal drivers propelling the growth of the global recombinant protein market. Innovations in gene editing tools, such as CRISPR-Cas9, have revolutionized the precision and efficiency of modifying host cells to express desired proteins. This breakthrough significantly streamlines the production process, reducing costs and accelerating the development timeline for recombinant proteins.

Furthermore, advancements in mammalian cell culture technologies have bolstered the scalability and yield of protein expression systems. Enhanced bioprocessing techniques, including perfusion systems and single-use bioreactors, contribute to higher productivity and cost-effectiveness in large-scale production. This increased efficiency not only meets the growing demand for biopharmaceuticals but also ensures a more sustainable and competitive market landscape. The integration of artificial intelligence and data analytics in optimizing protein expression further refines the selection of host cells and cultivation conditions, maximizing protein yield and quality. These technological strides not only enhance production capabilities but also address the industry's evolving needs for diverse and complex recombinant proteins. As the synergy of these advancements continues to reshape the biopharmaceutical landscape, the global recombinant protein market stands poised for dynamic growth, offering substantial opportunities for stakeholders to capitalize on the evolving technological frontier.

Growing Prevalence of Chronic Diseases

The escalating prevalence of chronic diseases is a key catalyst propelling the growth of the global recombinant protein market. As the incidence of conditions such as diabetes, cancer, and autoimmune disorders rises globally, there is a parallel surge in demand for advanced biopharmaceuticals, driving the need for recombinant proteins. Recombinant proteins play a pivotal role in the development of therapeutic interventions for chronic diseases, offering targeted and effective treatments. The specificity and diversity of these proteins make them essential in addressing the complex molecular pathways associated with chronic illnesses, providing more precise and personalized solutions.

Moreover, as the aging population increases, there is a higher likelihood of individuals developing chronic conditions, further amplifying the demand for innovative biopharmaceuticals. The flexibility of recombinant protein technology allows for the creation of a wide range of therapeutic proteins, catering to the diverse needs of patients with various chronic diseases. In response to this growing health crisis, pharmaceutical companies are intensifying their research and development efforts to bring novel recombinant protein-based therapies to market. As a result, the global recombinant protein market is positioned for significant expansion, presenting lucrative opportunities for industry stakeholders to meet the rising demand for effective and targeted treatments in the realm of chronic diseases.

Key Market Challenges

Cost and Complexity of Production

The growth of the global recombinant protein market faces potential hindrances due to the cost and complexity associated with production. The intricate nature of manufacturing these proteins, often requiring advanced biotechnological processes, poses challenges in terms of operational expenses and resource utilization. The complexity of upstream and downstream processing, including cell culture maintenance, purification, and formulation, contributes significantly to the overall production costs.

Moreover, stringent regulatory requirements for ensuring the safety and quality of recombinant proteins add another layer of complexity, demanding robust infrastructure and compliance measures. The need for specialized facilities and skilled personnel further amplifies the operational expenses, creating barriers for smaller companies entering the market. As a consequence, the high production costs may translate into elevated prices for recombinant protein-based therapeutics, potentially limiting patient access and adoption. Furthermore, the capital-intensive nature of production facilities and the time-intensive development processes may deter some players from engaging in the market, hindering its overall growth potential. Addressing these challenges necessitates ongoing innovation in production technologies and cost-effective solutions. Collaborations, technological advancements, and strategic investments are crucial for mitigating cost and complexity concerns, ensuring the sustained growth of the global recombinant protein market while making these biopharmaceuticals more accessible and commercially viable.

Quality Control and Consistency

Quality control and consistency challenges present potential impediments to the growth of the global recombinant protein market. Ensuring the reproducibility and uniformity of recombinant proteins is a critical aspect of regulatory compliance and therapeutic efficacy. Variability in production processes and inherent biological systems can lead to inconsistencies in product quality, posing risks to patient safety and treatment outcomes.

Implementing rigorous quality control measures throughout the production cycle, from cell culture to purification and formulation, adds complexity and cost to the manufacturing process. Ensuring batch-to-batch consistency becomes particularly challenging due to the sensitivity of biological systems to environmental factors and subtle process variations. Regulatory bodies demand strict adherence to quality standards, making it imperative for manufacturers to invest in sophisticated quality control infrastructure and expertise. The need for robust quality assurance measures not only increases operational costs but also extends the time required for product development and market entry. Achieving the delicate balance between meeting regulatory requirements and maintaining cost-effectiveness remains a significant hurdle, potentially hindering the overall growth trajectory of the global recombinant protein market. Continuous advancements in analytical technologies and standardized quality control protocols are essential for overcoming these challenges and establishing a reliable and sustainable framework for the production of recombinant proteins.

Key Market Trends

Expansion of Therapeutic Applications

The expansion of therapeutic applications stands as a powerful driver fueling the growth of the global recombinant protein market. As scientific understanding of molecular pathways deepens, there is a burgeoning realization of the diverse therapeutic potential offered by recombinant proteins. Beyond their traditional applications in treating conditions such as diabetes and cancer, these proteins are increasingly finding utility in addressing a broad spectrum of diseases, including rare genetic disorders and autoimmune conditions.

The versatility of recombinant proteins allows for the development of targeted and personalized therapies, aligning with the trend toward precision medicine. This broadening scope of applications not only enhances the market's commercial potential but also positions recombinant proteins as indispensable tools in the evolving landscape of modern medicine. Furthermore, ongoing research and development efforts are uncovering novel therapeutic targets, expanding the repertoire of conditions that can be effectively addressed with recombinant protein-based interventions. The dynamic interplay between scientific innovation and therapeutic applications creates a robust ecosystem, fostering continuous growth in the global recombinant protein market. Stakeholders in the biopharmaceutical industry are well-positioned to capitalize on this trend, as the market evolves to meet the increasing demand for innovative and targeted therapeutic solutions across a spectrum of medical conditions.

Focus on Sustainable Biomanufacturing

The focus on sustainable biomanufacturing emerges as a pivotal driver propelling the growth of the global recombinant protein market. As environmental consciousness takes center stage in the business landscape, biopharmaceutical companies are increasingly adopting sustainable practices in protein production. Sustainable biomanufacturing encompasses strategies to minimize carbon footprint, reduce energy consumption, and optimize resource utilization throughout the recombinant protein manufacturing process. In response to market demands and regulatory pressures, companies are investing in innovative technologies and green initiatives, such as single-use bioreactors, renewable energy sources, and eco-friendly purification processes. These measures not only align with corporate social responsibility but also enhance operational efficiency and cost-effectiveness. Moreover, a commitment to sustainable biomanufacturing resonates positively with consumers and stakeholders, fostering a positive brand image and creating a competitive edge. The integration of sustainable practices not only addresses environmental concerns but also positions the industry to meet the rising demand for ethical and eco-friendly biopharmaceutical products. As the global community increasingly values sustainability, the incorporation of green technologies and practices in recombinant protein production not only contributes to environmental stewardship but also serves as a catalyst for the continued growth and resilience of the global recombinant protein market.

Segmental Insights

Product Insights

Based on the Product, the antibody segment is anticipated to witness substantial market growth throughout the forecast period. The exponential growth of the global recombinant protein market is notably steered by the burgeoning demand for antibody products. Antibodies, with their pivotal role in targeted therapies and diagnostics, stand at the forefront of biopharmaceutical innovation. The increasing prevalence of chronic diseases, including cancer and autoimmune disorders, underscores the need for precise and efficacious treatments, propelling the demand for recombinant antibody-based therapeutics. The versatility of recombinant antibody technology allows for the engineering of monoclonal antibodies with enhanced specificity and reduced immunogenicity, addressing limitations associated with traditional therapeutic approaches. The development of novel antibodies for emerging infectious diseases and the expansion of personalized medicine further amplify the market's growth trajectory. Moreover, strategic collaborations and partnerships within the biopharmaceutical industry contribute to a robust pipeline of antibody products. These collaborations foster innovation, accelerate research and development efforts, and drive commercialization. As healthcare systems worldwide increasingly prioritize biologics and targeted therapies, the global recombinant protein market, propelled by the prominence of antibody products, stands poised for sustained expansion, offering lucrative opportunities for industry stakeholders to address evolving medical needs.

Application Insights

Based on the Application segment, the Therapeutic Use segment has been the dominant force in the market. The growth of the global recombinant protein market is strongly propelled by the expanding therapeutic applications of these biopharmaceuticals. Recombinant proteins serve as crucial components in the development of therapeutic interventions for a diverse range of medical conditions. From treating chronic diseases such as diabetes and cancer to addressing rare genetic disorders and autoimmune conditions, the therapeutic versatility of recombinant proteins positions them at the forefront of modern medicine. The trend towards personalized medicine further accentuates the significance of recombinant proteins, allowing for the customization of therapeutic solutions tailored to individual patient profiles. As advancements in biotechnology continue to unravel novel therapeutic targets, the demand for recombinant proteins is set to grow. Furthermore, the ongoing research and development efforts aimed at expanding the therapeutic repertoire of recombinant proteins, coupled with the regulatory support for these innovative treatments, create a conducive environment for market growth. With the continuous emergence of groundbreaking therapies, the global recombinant protein market becomes integral to addressing the evolving landscape of healthcare needs, offering immense opportunities for biopharmaceutical companies to contribute to and benefit from the advancements in therapeutic applications.

Regional Insights

North America, specifically the Recombinant Protein Market, dominated the market in 2022, primarily due to The North America region is poised to be a major driving force behind the growth of the global recombinant protein market. Several factors contribute to this prominence. Firstly, North America boasts a robust and well-established biopharmaceutical industry, with key players continually investing in research and development initiatives. This region's advanced infrastructure, technological capabilities, and skilled workforce create an environment conducive to innovation in recombinant protein production. Additionally, the region benefits from a favorable regulatory landscape that facilitates efficient product approvals and commercialization. The stringent quality standards and regulatory frameworks inspire confidence among investors and consumers, promoting the development and adoption of recombinant protein-based therapeutics. Moreover, the prevalence of chronic diseases in North America, coupled with a rapidly aging population, fuels the demand for advanced biopharmaceutical solutions, further driving the growth of the recombinant protein market. Collaborations between academic institutions, research organizations, and industry players in the region also contribute to a dynamic ecosystem that fosters continuous advancements in biotechnology.

Key Market Players

Abbvie Inc.

Amgen Inc.

Bio-Rad Laboratories Inc.

Eli Lilly and Company

Merck KGaA

Novo Nordisk AS

Sanofi SA

Thermo Fisher Scientific Inc.

Novartis AG

GlaxoSmithKline PLC

Novavax Inc.

Pfizer Inc.

Report Scope:

In this report, the Global Recombinant Protein Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Recombinant Protein Market, By Products:

Hormone
Growth Factor
Antibody
Enzyme
Other

Recombinant Protein Market, By Application:

Research Application
Therapeutic Use
Biotechnology Industry

Recombinant Protein Market, By Region:

North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
Turkey
Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Recombinant Protein Market.

Available Customizations:

Global Recombinant Protein market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Recombinant Protein Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Product (Hormone, Growth Factor, Antibody, Enzyme, Other)
- 5.2.2. By Application (Research Application, Therapeutic Use, Biotechnology Industry)
- 5.2.3. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
- 5.2.4. By Company (2022)
5.3. Market Map
- 5.3.1 By Product
- 5.3.2 By Application
- 5.3.3 By Region

6. North America Recombinant Protein Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Product (Hormone, Growth Factor, Antibody, Enzyme, Other)
- 6.2.2. By Application (Research Application, Therapeutic Use, Biotechnology Industry)
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Recombinant Protein Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Product
    - 6.3.1.2.2. By Application
- 6.3.2. Canada Recombinant Protein Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Product
    - 6.3.2.2.2. By Application
- 6.3.3. Mexico Recombinant Protein Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Product
    - 6.3.3.2.2. By Application

7. Europe Recombinant Protein Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Product (Hormone, Growth Factor, Antibody, Enzyme, Other)
- 7.2.2. By Application (Research Application, Therapeutic Use, Biotechnology Industry)
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. France Recombinant Protein Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Product
    - 7.3.1.2.2. By Application
- 7.3.2. Germany Recombinant Protein Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Product
    - 7.3.2.2.2. By Application
- 7.3.3. United Kingdom Recombinant Protein Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Product
    - 7.3.3.2.2. By Application
- 7.3.4. Italy Recombinant Protein Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Product
    - 7.3.4.2.2. By Application
- 7.3.5. Spain Recombinant Protein Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Product
    - 7.3.5.2.2. By Application

8. Asia-Pacific Recombinant Protein Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Product (Hormone, Growth Factor, Antibody, Enzyme, Other)
- 8.2.2. By Application (Research Application, Therapeutic Use, Biotechnology Industry)
- 8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Recombinant Protein Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Product
    - 8.3.1.2.2. By Application
- 8.3.2. India Recombinant Protein Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Product
    - 8.3.2.2.2. By Application
- 8.3.3. Japan Recombinant Protein Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Product
    - 8.3.3.2.2. By Application
- 8.3.4. South Korea Recombinant Protein Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Product
    - 8.3.4.2.2. By Application
- 8.3.5. Australia Recombinant Protein Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Product
    - 8.3.5.2.2. By Application

9. South America Recombinant Protein Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Product (Hormone, Growth Factor, Antibody, Enzyme, Other)
- 9.2.2. By Application (Research Application, Therapeutic Use, Biotechnology Industry)
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Recombinant Protein Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Product
    - 9.3.1.2.2. By Application
- 9.3.2. Argentina Recombinant Protein Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Product
    - 9.3.2.2.2. By Application
- 9.3.3. Colombia Recombinant Protein Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Product
    - 9.3.3.2.2. By Application

10. Middle East and Africa Recombinant Protein Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Product (Hormone, Growth Factor, Antibody, Enzyme, Other)
- 10.2.2. By Application (Research Application, Therapeutic Use, Biotechnology Industry)
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Recombinant Protein Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Product
    - 10.3.1.2.2. By Application
- 10.3.2. Saudi Arabia Recombinant Protein Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Product
    - 10.3.2.2.2. By Application
- 10.3.3. UAE Recombinant Protein Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Product
    - 10.3.3.2.2. By Application

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches

13. Global Recombinant Protein Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Abbvie Inc.
- 15.1.1. Business Overview
- 15.1.2. Product Offerings
- 15.1.3. Recent Developments
- 15.1.4. Financials (As Reported)
- 15.1.5. Key Personnel
- 15.1.6. SWOT Analysis
15.2. Amgen Inc.
15.3. Bio-Rad Laboratories Inc.
15.4. Eli Lilly and Company
15.5. Merck KGaA
15.6. Novo Nordisk AS
15.7. Sanofi SA
15.8. Thermo Fisher Scientific Inc.
15.9. Novartis AG
15.10. GlaxoSmithKline PLC
15.11. Novavax Inc.
15.12. Pfizer Inc.